Raxibacumab
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Raxibacumab: From Inhalational Anthrax to Postinfectious Vasculitis
One-Sentence Summary
Raxibacumab is a monoclonal antibody originally used to treat inhalational anthrax and anthrax infection. The TxGNN model predicts it may be effective for postinfectious vasculitis, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inhalational anthrax; anthrax infection |
| Predicted New Indication | Postinfectious vasculitis |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| US Market Status | Cancelled only |
| Number of NDAs | 1 (BLA) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, raxibacumab is a monoclonal antibody that neutralizes the protective antigen (PA) of Bacillus anthracis, blocking anthrax toxin from entering cells. Its efficacy is relevant to anthrax toxin-mediated disease.
A mechanistic link to postinfectious vasculitis is weak. Postinfectious vasculitis is generally immune-complex or immune-mediated, and no plausible connection to the anti-PA mechanism was identified. The high TxGNN score (99.75%) is a computational prediction only and is not backed by trials or literature.
Other top-ranked predictions show the same pattern: post-infectious syndrome, post-bacterial disorder, infective urethral stricture, otitis externa, Chagas cardiomyopathy, infection-related hemolytic uremic syndrome, and drug-induced osteoporosis. All have scores between 99.2% and 99.7%, all are evidence level L5, and none has a clear mechanistic rationale. Infection-related hemolytic uremic syndrome is conceptually analogous (toxin neutralization), but it is driven by Shiga toxin, which raxibacumab does not target.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125349 (cancelled) | Raxibacumab (Emergent Manufacturing Operations Baltimore LLC) | Injection | Not listed in the data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical trials or literature behind it (evidence level L5), and the anti-PA mechanism has no plausible link to postinfectious vasculitis. The only US license is cancelled, and safety and mechanism data are incomplete.
To proceed, the following is needed:
- Package insert warnings and contraindications (required before any safety screening)
- Detailed mechanism of action data
- A mechanistic rationale connecting anti-PA toxin neutralization to vasculitis pathophysiology
- Preclinical or literature evidence supporting the indication
- Route and dosage compatibility assessment for the new indication
- Clarification of the cancelled US license status and product availability
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.